吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性的meta分析  

Meta-analysis of the efficacy and safety of gemcitaine combined with tipifarnibin the treatment of pancreatic cancer

作　　者：王灵芝 唐松云 涂剑[1,3] 谢伟全[1,3] WANG Lingzhi;TANG Songyun;TU Jian;XIE Weiquan(the Cooperative Innovation Center for Molecular Targeting New Drug Study,University of South China,Hu’nan Hengyang 421001,China;Hengyang Central Hospital,Hu’nan Hengyang 421001,China;Institute of Pharmacy&Pharmacology,University of South China,Hu’nan Hengyang 421001,China)

机构地区：[1]南华大学分子靶标新药研究协同创新中心,湖南衡阳421001 [2]衡阳市中心医院,湖南衡阳421001 [3]南华大学药物药理研究所,湖南衡阳421001

出　　处：《上海医药》2020年第5期34-39,共6页Shanghai Medical & Pharmaceutical Journal

基　　金：南华大学分子靶标新药研究协同创新中心大学创新性实验计划项目(项目编号0223-0002-00008);湖南省分子靶标协同创新中心中青年创新人才培养项目(项目编号0223-0002-0002000-51)。

摘　　要：目的:评价吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性。方法:通过计算机检索Cochrane Library、PubMed、中国生物医学文献数据库、中国知网和万方等数据库,收集吉西他滨联合替吡法尼治疗胰腺癌的临床随机对照试验(RCT),对吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性进行meta分析。结果:最终纳入2项RCT,共计932例患者。meta分析结果显示:吉西他滨联合替吡法尼治疗胰腺癌,对延长胰腺癌患者生存期无明显优势(P>0.05),且会提高患者中性粒细胞减少和周围神经病变的发生率,但可以降低患者呼吸困难的发生率。结论:吉西他滨与替吡法尼联合用药与吉西他滨单药治疗胰腺癌相比没有显著的优越性。Objective:To assess the e fficacy and safety of gemcitabine plus tipifarnib for the treatment of pancreatic cancer by meta-analysis.Methods:The data from some randomized controlled trials(RCT)of gemcitabine plus teprefini in the treatment of pancreatic cancer were collected by searching for Cochrane Library,PubMed,CBM,CNKI,and Wanfang database and their efficacy and safety were analyzed using RevMan 5.3 software.Results:A total of 2 studies and 932 patients were included.The results of meta-analysis indicated that the combination chemotherapy of gemcitabine and teprefini in the treatment of pancreatic cancer had no significant advantage in prolonging the survival of patients with pancreatic cancer compared with the single-agent chemotherapy(P>0.05),and would increase the incidence of neutropenia and peripheral neuropathy but could reduce the incidence of dyspnea in patients.Conclusion:The combination medication has no significant advantages compared with gemcitabine monotherapy for pancreatic cancer.

关 键 词：吉西他滨 替吡法尼 胰腺癌 META 分析 

分 类 号：R979.19[医药卫生—药品] R735.9[医药卫生—药学]